Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration

Abstract

Background: Atorvastatin and metformin both have pleiotropic effects. Whether atorvastatin combined with metformin could provide additive benefits on subjects with dyslipidemia and overweight/obese is unknown. And the mechanism is also not fully clear yet.

Methods: A cross-sectional research was performed and 130 subjects with dyslipidemia and overweight/obese were enrolled and randomly assigned into combined group (20 mg of atorvastatin daily plus 500 mg of metformin twice daily) and control group (20 mg of atorvastatin daily). At baseline and 8 weeks later, parameters of interest were recorded and fasting venous blood was drawn for laboratory examination.

Results: The rates of overweight (76.9% vs. 73.8%) and obese (23.1% vs. 26.2%) in both group were comparable. Dyslipidemia in both groups were featured by increased serum levels of triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). Serum level of high sensitivity C-reactive protein (Hs-CRP) was comparably elevated in both groups at baseline, and leukocyte rho-associated kinase 2 (ROCK2) and serum nitric oxide (NO) concentrations were also comparable. Generally, the baseline characteristics between these 2 groups were no significant differences. 8 weeks later, compared to baseline, body mass index (BMI), the rates of overweight and obese, daily exercise time, smoking status, lipid profiles, Hs-CRP level, leukocyte ROCK2 and serum NO concentrations in both groups were improved. Notably, compared to control group, the rate of obese, Hs-CRP level, leukocyte ROCK2 and serum NO concentrations were improved more profoundly in the combined group (p<0.05). After adjusted for age, gender, BMI, TG, LDL-C, Hs-CRP and exercise time, atorvastatin plus metformin was positively associated with serum NO concentration, with odds ratio (OR) of 1.146 (95% confidence interval (CI) 1.089–1.164, combined group vs. control group, p<0.05), and inversely associated with leukocyte ROCK2 concentration, with OR of 0.853 (95% CI 0.834–0.872, combined group vs. control group, p<0.05).

Conclusion: In subjects with dyslipidemia and overweight/obese, atorvastatin plus metformin may confer additive benefits through reducing leukocyte ROCK2 concentration.

Key words

atorvastatin - dyslipidemia - mechanism

^* co-first authors

• References

• 1 Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-S45
• 2 Tete S, Tripodi D, Rosati M et al. Endothelial cells, cholesterol, cytokines, and aging. Int J Immunopathol Pharmacol 2012; 25: 355-363
• 3 Ye Y, Zhao X, Zhai G et al. Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther 2012; 17: 357-365
• 4 Huang C, Cen C, Wang C et al. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis 2014; 13: 67
• 5 Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007; 59: 483-499
• 6 Balakumar P, Kathuria S, Taneja G et al. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins. J Mol Cell Cardiol 2012; 52: 83-92
• 7 Koh KK, Son JW, Ahn JY et al. Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. Atherosclerosis 2004; 177: 147-153
• 8 Abdel-Zaher AO, Elkoussi AE, Abudahab LH et al. Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein. Fundam Clin Pharmacol 2012; 26: 701-711
• 9 Cai A, Zhou Y, Li L. Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins. J Am Heart Assoc 2015; 4: e002113
• 10 Hidaka T, Hata T, Soga J et al. Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers. Hypertens Res 2010; 33: 354-359
• 11 Liu PY, Liu YW, Lin LJ et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009; 119: 131-138
• 12 Shimizu K, Aikawa M, Takayama K et al. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003; 108: 2113-2120
• 13 Vaughan CJ, Gotto Jr AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10
• 14 Zheng C, Azcutia V, Aikawa E et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J 2013; 34: 615-624
• 15 Liu Y, Huang C, Ceng C et al. Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia. Lipids Health Dis. 2014; 13: 115
• 16 Jensen MD, Ryan DH, Apovian CM et al. 2013; AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129: S102-S138
• 17 He H, Zhao Z, Chen J et al. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. J Hypertens 2012; 30: 1430-1439
• 18 Deans KA, Sattar N. “Anti-inflammatory” drugs and their effects on type 2 diabetes. Diabetes Technol Ther 2006; 8: 18-27
• 19 Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006; 290: C661-C668
• 20 Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32: 167-173
• 21 Okamoto R, Li Y, Noma K et al. FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 2013; 27: 1439-1449
• 22 Zhao Z, Rivkees SA. Rho-associated kinases play a role in endocardial cell differentiation and migration. Dev Biol 2004; 275: 183-191
• 23 Shimizu T, Fukumoto Y, Tanaka S et al. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arterioscler Thromb Vasc Biol 2013; 33: 2780-2791
• 24 Kaneider NC, Egger P, Dunzendorfer S et al. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 2002; 22: 1029-1035
• 25 Rawlings R, Nohria A, Liu PY et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 2009; 103: 437-441
• 26 Calvert JW, Gundewar S, Jha S et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008; 57: 696-705
• 27 Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44-6S52
• 28 Farah S, Agazie Y, Ohan N et al. A rho-associated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin signaling. J Biol Chem 1998; 273: 4740-4746
• 29 Gundewar S, Calvert JW, Jha S et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009; 104: 403-411